Get started
Nektar TherapeuticsNektar TherapeuticsNektar Therapeutics

Nektar Therapeutics

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

NKTR trade ideas

No jump before earnings; Drop to $30? $25? $20? $Sideways? Can't get back above 0 on MACD. Can't get back above 50 on Stoch RSI. TradingNewsNow claims an intrinsic value per share above $130. Results and Presentations seem to not be helping. I'd "like" to see $41/share, but $24/share might be more the direction of Nektar Therapeutics before a rebound. Continuing to watch sideways movements between $30-$37 in the meantime. Not a broker, nor is this financial advice. I had Nektar hope in opioid replacements for pain therapy and immuno-oncology therapies. I guess they simply cannot beat cannabis in providing quality of life.
NASDAQ:NKTR
by QUINNsNextStep
NKTR Short-term downside?: More Patterns for considerationMy chart is getting a bit messy, however, this one does shoe a consistent pattern on both MACD and Stochastic RSI, making this either the BEST time to BUY, or the WORST time to BUY. It may break $50/share by the end of summer, and End of February Earnings could rebound the stock up to $70+ on the Bullish Side over 3-6 months. On the Bearish side, I am still looking at previous numbers $25-$37/share before any additional rebound. Again, barring any medical breakthroughs. NOT FINANCIAL ADVICE. Let me know what you think of my ideas, any counter reasoning, or other pertinent/interesting information pertaining to Nektar Therapeutics. Thanks.
NASDAQ:NKTRLong
by QUINNsNextStep
NKTR SHORT 1-Year, Historical supports show more downside.I joined NKTR at the ~12.67 in Jan. 2017. I did not see this historical chart prior to selling early 2018, and then upping the ante throughout 2018, learning more about options contracts as well. Now that I am at a loss of ~$8K, with a cost basis in the mid-40's, I see that even though Bristol-Myers Squibb made a huge investment, the trend should continue downward, barring any medical break-through, reaching supports around $28, $22, and $16. NOT FINANCIAL ADVICE. Let me know what you think. Leave a comment below. Thank you for the consideration.
NASDAQ:NKTRLong
by QUINNsNextStep
Nektar SHORTShort from 103.5 but expect some further buying could see some profit taking by institutions over coming months. - $1bn short interest - 189.82 price to book ratio shows the inflated share price. - 1.96 beta - Considering its returned 549.33% in the past year and is already up 70.81% YTD and is 97.28% institutionally owned is of concern if earnings miss estimates/drugs fail and the institutions start profit taking. - Nektar relies heavily on partners such as AstraZeneca and Shire for revenues in the form of equity investment, collaboration milestone payments and license. - Given the royalty opportunity associated with Movantik and Adynovate with AstraZeneca and Shire. - The level of sales achieved by NYSE:AZN and LSE:SHP will have a significant impact on NKTR financial condition over the next few years. If these drugs fail to achieve success commercially or if the candidates in the development stages fail to generate positive outcomes sufficient to regulatory approval in major markets it could significantly affect the share price and companies access to capital necessary for its R&D. - Gaining approval for candidates has become more difficult with a tightening regulatory environment. - Return on Equity -156.85% - Debt/Capital - 73.63% - Earning Yield (1.29%) NeroTree Capital rates Nektar Therapeutics as a SELL with a price target of $80 over the next 52w.
NASDAQ:NKTRShort
by UnknownUnicorn2415222
2